688068.SHG Beijing Hotgen Biotech Co Ltd
- Market cap
- CNY 6.68B
- P/E
- -
- P/B
- 2.54x
- ROE
- -11.8%
- Dividend yield
- 0.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688068.SHG undervalued?
Graham numberThe Graham number of Beijing Hotgen Biotech Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing Hotgen Biotech Co Ltd fundamental analysis
No fundamental analysis for Beijing Hotgen Biotech Co Ltd yet.
Beijing Hotgen Biotech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers nucleic acid drugs, antibody drugs, and biotechnology health and beauty consumer products. The company also provides clinical diagnostics and product solutions, including Upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for te…
Full company profileBeijing Hotgen Biotech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing Hotgen Biotech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 122M | 142M | 187M | 210M | 514M | 5.37B | 3.56B | 548M | 511M | 408M | 500M |
| Gross Profit | 92.7M | 105M | 138M | 154M | 324M | 3.12B | 1.79B | 336M | 254M | 408M | 319M |
| Operating Income | 30.1M | 34.6M | 55.8M | 37.4M | 128M | 2.58B | 1.09B | 18.7M | -186M | -263M | -327M |
| EBITDA | 41.4M | 45.0M | 72.2M | 61.2M | 157M | 2.64B | 1.17B | 77.3M | -103M | -180M | -351M |
| Net Income | 28.8M | 30.1M | 48.1M | 33.9M | 112M | 2.19B | 945M | 28.9M | -191M | -211M | -278M |
| EPS | 0.44 | 0.43 | 0.70 | 0.45 | 1.22 | 24 | 10 | 0.33 | -2.07 | -2.24 | -3.00 |
| Balance Sheet | |||||||||||
| Total Assets | 160M | 190M | 267M | 726M | 903M | 3.64B | 3.90B | 3.56B | 3.33B | 3.18B | 2.95B |
| Total Liabilities | 29.1M | 28.0M | 56.7M | 76.4M | 156M | 771M | 546M | 203M | 252M | -2.93B | 464M |
| Shareholders' Equity | 131M | 162M | 210M | 645M | 743M | 2.84B | 3.34B | 3.37B | 3.08B | 2.93B | 2.36B |
| Cash & Short-term Investments | 96.5M | 48.6M | 63.8M | 423M | 383M | 2.09B | 1.41B | 552M | 472M | 1.09B | 192M |
| Total Debt | 3.18M | 156K | - | 23.8M | 26.5M | 36.0M | 42.1M | 15.3M | 121K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 45.5M | 23.0M | 55.0M | 19.4M | 165M | 2.64B | 979M | -25.4M | -37.2M | -83.4M | - |
| Capital Expenditure | 21.2M | 69.0M | 42.0M | 88.5M | 172M | 399M | 565M | 413M | 51.4M | 43.6M | 117M |
| Free Cash Flow | 24.4M | -46.1M | 13.0M | -69.1M | -7.65M | 2.25B | 414M | -465M | -88.6M | -127M | -363M |
| Ratios | |||||||||||
| ROE | 22.0% | 18.6% | 22.9% | 5.3% | 15.1% | 76.9% | 28.3% | 0.9% | -6.2% | -7.2% | -11.8% |
| ROA | 18.0% | 15.9% | 18.0% | 4.7% | 12.4% | 60.0% | 24.2% | 0.8% | -5.7% | -6.6% | -9.4% |
| Net Profit Margin | 23.6% | 21.2% | 25.7% | 16.1% | 21.8% | 40.7% | 26.6% | 5.3% | -37.4% | -51.6% | -55.7% |
| Debt to Equity | 0.02x | 0.00x | - | 0.04x | 0.04x | 0.01x | 0.01x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing Hotgen Biotech Co Ltd dividends
- Dividend yield
- 0.03%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 3, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.74M | 0.02 | - |
| 2024 | CNY 17.3M | 0.19 | - |
| 2023 | - | - | - |
| 2022 | CNY 311M | 3.38 | 32.9% |
| 2021 | CNY 93.3M | 1.01 | 4.3% |
| 2020 | CNY 18.7M | 0.20 | 16.6% |
| 2019 | CNY 1.03M | 0.01 | 3.1% |
| 2018 | CNY 3.28K | 0.00 | 0.0% |
| 2017 | CNY 26.6K | 0.00 | 0.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.48:1 on Jun 16, 2022.
Who owns Beijing Hotgen Biotech Co Ltd
- Insiders 32.20%
- Institutions 18.28%
- Public & others 49.52%
- Shares outstanding 92.8M
- Free float 64.1M
Beijing Hotgen Biotech Co Ltd company profile
- Company name
- Beijing Hotgen Biotech Co Ltd
- Ticker
- 688068.SHG
- ISIN
- CNE100003P82
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 946
- Fiscal year end
- December
- Address
- No. 55, Qingfeng West Road, Beijing, China, 102629
- Phone
- 86 10 5098 6527
- Website
- hotgen.com.cn
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers nucleic acid drugs, antibody drugs, and biotechnology health and beauty consumer products. The company also provides clinical diagnostics and product solutions, including Upconversion light, chemiluminescence, sugar capture, microfluidics, and genetic testing for testing of intestinal microorganisms, gastrointestinal foodborne infections, insect-borne diseases, respiratory pathogens, infectious diseases, Ebola virus antigen, biological warfare agents, microorganisms, and mycotoxins. Beijing Hotgen Biotech Co., Ltd. was founded in 2005 and is based in Beijing, China.
Beijing Hotgen Biotech Co Ltd management
9- Mr. Changqing LinChairman & GM · born 1976
- Mr. Zhongchao JieFinancial Director & Accounting Supervisor · born 1980
- Mr. Yongzhan ShiDeputy GM, Secretary & Director · born 1982
- Ms. Jia LiuDeputy General Manager · born 1987
- Ms. Hongrui ZhangCore Technical Personnel · born 1986
- Ms. Suhong ChenCore Technical Personnel · born 1986
- Ms. Yong QiaoCore Technical Personnel · born 1983
- Mr. Kun HaoCore Technical Personnel · born 1986
- Mr. Zhihui XuCore Technical Personnel · born 1982